amylin


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to amylin: Symlin

am·y·lin

(am'i-lin),
A 37-amino acid peptide that is cosecreted with insulin from the pancreatic β-cell. Many of its biologic activities mimic those of calcitonin gene-related peptide, which is not a β-cell peptide. In patients with Type 1 diabetes, amylin is essentially absent from the plasma. The plasma level of amylin rises after a meal or a glucose load.
[amyloid + -in]

amylin

(ăm′ə-lĭn)
n.
1. A peptide hormone that is secreted along with insulin by the beta cells of the pancreas and helps to regulate blood sugar levels by inhibiting glucagon secretion and by slowing the rate at which food leaves the stomach.
2. Archaic Any of various components of starch.

amylin

An older term for:
(1) (Pancreatic) islet amyloid polypeptide;
(2) Amylopectin.

am·y·lin

(am'i-lin)
The cellulose of starch; the insoluble envelope of starch grains.

amylin

see amyloid.
References in periodicals archive ?
The success of the tender offer for Amylin is subject to securing at least a majority of the targeta[euro](tm)s shares as well as the Hart-Scott-Rodino (HSR) clearance, the buyer said today.
Amylin is committed to delivering novel therapies that transform the way diabetes and other metabolic disorders are treated.
Under the terms of the definitive merger agreement between Bristol-Myers Squibb and Amylin, Bristol-Myers Squibb will commence a cash tender offer to purchase all of the outstanding shares of Amylin's common stock for USD31.
The agreement follows a several months long strategic review of options by Amylin focused on finding a way to maximise the value of its diabetes franchise, the CEO added.
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Amylin.
Amylin had previously rebuffed an unsolicited advance by US Bristol-Myers Squibb Company (NYSE:BMY) of USD22.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, relating to the acquisition of Amylin by Bristol-Myers Squibb and the discovery, development and commercialization of certain biological compounds.
Country: USASector: PharmaceuticalsTarget: Amylin Pharmaceuticals Inc Buyer: Bristol Myers Squibb Co Deal size in USD: 3.
As part of the deal, the companies will transition full responsibility for the worldwide development and commercialization of exenatide to Amylin, starting in the US on 30 November 2011 and progressing to all markets by the end of 2013.
chairman and chief executive officer of Amylin, calls the collaboration with Lilly a significant step for his company.
M2 EQUITYBITES-August 9, 2012-Bristol-Myers Squibb completes cash tender offer for Amylin Pharmaceuticals at USD31.